| Parameter . | All EATL (n = 63) . | Type I (n = 41) . | Type II (n = 23) . |
|---|---|---|---|
| Number (percentage) of cases . | |||
| Sex | |||
| Male | 33 (48) | 18 (44) | 12 (52) |
| Female | 36 (52) | 23 (56) | 11 (48) |
| Race | |||
| African-American | 2 (3) | 1 (2) | 1 (4) |
| Caucasian | 56 (81) | 38 (93) | 13 (57) |
| Asian | 10 (14) | 1 (2) | 9 (39) |
| Age at diagnosis (yr) | |||
| Median (range) | 62.0 (36.0–92.0) | 64.0 (36–92) | 59.0 (39.0–89.0) |
| Celiac disease | |||
| Yes | 35 (61) | 32 (84) | 3 (16) |
| Adherence to gluten-free diet | |||
| Yes | 15 (36) | 15 (44) | 0 (0) |
| HLA type | |||
| DQ2/DQ8 | 49 (71) | 36 (88) | 10 (43) |
| Tumor location | |||
| Small intestine | 61 (93) | 40 (97) | 20 (91) |
| Size of tumor (cm) | |||
| Median (range) | 7.0 (1.5–75.0) | 8.0 (1.5–75.0) | 6.0 (2.0–23.0) |
| Histopathology | |||
| CD3+ | 57 (85) | 30 (75) | 23 (100) |
| CD4− | 50 (91) | 29 (91) | 18 (95) |
| CD8+ | 31 (46) | 15 (37) | 15 (68) |
| CD56+ | 19 (33) | 2 (5) | 17 (85) |
| T cell receptor | |||
| AB | 16 (46) | 12 (43) | 4 (57) |
| GD | 9 (26) | 6 (21) | 3 (43) |
| ECOG performance score | |||
| 0–1 | 20 (48) | 14 (50) | 6 (43) |
| 2–4 | 22 (52) | 14 (50 | 8 (57) |
| Ann Arbor stage | |||
| I | 17 (40) | 10 (36) | 7 (47) |
| II | 18 (42) | 14 (50) | 4 (27) |
| III–IV | 8 (19) | 4 (14) | 4 (27) |
| High LDH | |||
| High LDH | 31 (89) | 21 (88) | 10 (91) |
| B symptoms | |||
| Yes | 27 (59) | 19 (63) | 7 (47) |
| Small bowel perforation | |||
| Yes | 33 (57) | 22 (58) | 11 (55) |
| Number of nodal sites | |||
| 0 | 23 (48) | 14 (48) | 9 (56) |
| 1 or more | 15 (52) | 15 (52) | 7 (44) |
| Bone marrow involvement | |||
| No | 32 (89) | 20 (91) | 12 (92) |
| Treatment type | |||
| Curative | 32 (64) | 19 (58) | 12 (75) |
| Minimal | 18 (36) | 14 (42) | 4 (25) |
| Response to initial treatment | |||
| CR | 22 (63) | 15 (71) | 7 (50) |
| PR | 5 (14) | 3 (14) | 2 (14) |
| NR | 8 (23) | 3 (14) | 5 (36) |
| Progression or relapse | |||
| No | 8 (24) | 6 (32) | 2 (14) |
| Yes | 25 (76) | 13 (68) | 12 (86) |
| Survival | |||
| Median overall survival | 10 mo | 9 mo | 11 mo |
| 1-yr survival rate | 44% | 41% | 50% |
| 2-yr survival rate | 27% | 31% | 19% |
| Parameter . | All EATL (n = 63) . | Type I (n = 41) . | Type II (n = 23) . |
|---|---|---|---|
| Number (percentage) of cases . | |||
| Sex | |||
| Male | 33 (48) | 18 (44) | 12 (52) |
| Female | 36 (52) | 23 (56) | 11 (48) |
| Race | |||
| African-American | 2 (3) | 1 (2) | 1 (4) |
| Caucasian | 56 (81) | 38 (93) | 13 (57) |
| Asian | 10 (14) | 1 (2) | 9 (39) |
| Age at diagnosis (yr) | |||
| Median (range) | 62.0 (36.0–92.0) | 64.0 (36–92) | 59.0 (39.0–89.0) |
| Celiac disease | |||
| Yes | 35 (61) | 32 (84) | 3 (16) |
| Adherence to gluten-free diet | |||
| Yes | 15 (36) | 15 (44) | 0 (0) |
| HLA type | |||
| DQ2/DQ8 | 49 (71) | 36 (88) | 10 (43) |
| Tumor location | |||
| Small intestine | 61 (93) | 40 (97) | 20 (91) |
| Size of tumor (cm) | |||
| Median (range) | 7.0 (1.5–75.0) | 8.0 (1.5–75.0) | 6.0 (2.0–23.0) |
| Histopathology | |||
| CD3+ | 57 (85) | 30 (75) | 23 (100) |
| CD4− | 50 (91) | 29 (91) | 18 (95) |
| CD8+ | 31 (46) | 15 (37) | 15 (68) |
| CD56+ | 19 (33) | 2 (5) | 17 (85) |
| T cell receptor | |||
| AB | 16 (46) | 12 (43) | 4 (57) |
| GD | 9 (26) | 6 (21) | 3 (43) |
| ECOG performance score | |||
| 0–1 | 20 (48) | 14 (50) | 6 (43) |
| 2–4 | 22 (52) | 14 (50 | 8 (57) |
| Ann Arbor stage | |||
| I | 17 (40) | 10 (36) | 7 (47) |
| II | 18 (42) | 14 (50) | 4 (27) |
| III–IV | 8 (19) | 4 (14) | 4 (27) |
| High LDH | |||
| High LDH | 31 (89) | 21 (88) | 10 (91) |
| B symptoms | |||
| Yes | 27 (59) | 19 (63) | 7 (47) |
| Small bowel perforation | |||
| Yes | 33 (57) | 22 (58) | 11 (55) |
| Number of nodal sites | |||
| 0 | 23 (48) | 14 (48) | 9 (56) |
| 1 or more | 15 (52) | 15 (52) | 7 (44) |
| Bone marrow involvement | |||
| No | 32 (89) | 20 (91) | 12 (92) |
| Treatment type | |||
| Curative | 32 (64) | 19 (58) | 12 (75) |
| Minimal | 18 (36) | 14 (42) | 4 (25) |
| Response to initial treatment | |||
| CR | 22 (63) | 15 (71) | 7 (50) |
| PR | 5 (14) | 3 (14) | 2 (14) |
| NR | 8 (23) | 3 (14) | 5 (36) |
| Progression or relapse | |||
| No | 8 (24) | 6 (32) | 2 (14) |
| Yes | 25 (76) | 13 (68) | 12 (86) |
| Survival | |||
| Median overall survival | 10 mo | 9 mo | 11 mo |
| 1-yr survival rate | 44% | 41% | 50% |
| 2-yr survival rate | 27% | 31% | 19% |